-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

701.P1.15 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, AML, antibodies, Biological, Animal models, bone marrow, Diseases, Non-Biological, Combinations, GVHD, Therapies, MDS, Biological Processes, enzyme inhibitors, gene therapy, Immune Disorders, Technology and Procedures, infusion, Study Population, Clinically relevant, genomics, Myeloid Malignancies, flow cytometry, immune mechanism, transplantation, inflammation, stem cells, pathways
Saturday, December 5, 2020: 7:00 AM-3:30 PM

Simona Pagliuca, MD1,2, Carmelo Gurnari, MD2,3*, Sanghee Hong, MD4, Cassandra M Kerr, MS2*, Sunisa Kongkiatkamon, MD2,5*, Hassan Awada, MD2, Ashwin Kishtagari, MBBS2, Misam Zawit, MBBS2*, Laila Terkawi2*, Valeria Visconte, PhD2, Eric D. Hsi, MD6, Betty K. Hamilton, MD7, Hetty E. Carraway, MD, MBA7, Navneet S. Majhail, MD, MS7 and Jaroslaw P. Maciejewski, MD, PhD8

1Université de Paris, Paris, France
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
4University Hospitals/ Case Western Reserve University, Cleveland, OH
5Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
6Department of Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH
7Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Eduardo Huarte, PhD1*, Michael Peel, PhD1*, Philip Dube, PhD2*, Lynn Stephens1*, Becky Stewart1*, Brian Long1*, Philip Czerniak1*, Julian Oliver, PhD1* and Paul Smith, PhD1*

1Incyte Corporation, Wilmington, DE
2Taconic Biosciences, Rensselaer, NY

Sydney Felker1,2*, Archana Shrestha3* and Punam Malik, MD1

1Cincinnati Children's Hospital Medical Center, Cincinnati, OH
2Immunology Graduate Program, University of Cincinnati College of Medicine, Cincinnati, OH
3Cincinnati Children's Hospital and Medical Center, Cincinnati, OH

Andriyana K Bankova, MD1*, Wendy W Pang, MD, PhD1, Brenda J Velasco1*, Janel R Long-Boyle, PharmD, PhD2,3* and Judith A Shizuru, MD, PhD1,4,5,6

1Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA
2Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California, San Francisco, Benioff Children's Hospital, San Francisco, CA
3Department of Clinical Pharmacy, University of California, San Francisco, Benioff Children’s Hospital, San Francisco, CA
4Institute for Stem Cell Biology and Regenerative Medicine, Stanford University Medical Center, Stanford, CA
5Stanford University School of Medicine, Stanford, CA
6Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University Medical Center, Stanford, CA

Kiyomi Mashima, MD, PhD1*, Kazuya Sato, MD, PhD1, Norihito Takayama1*, Junko Izawa1*, Takashi Ikeda, M.D.1*, Kento Umino, MD1*, Hirofumi Nakano, MD1*, Daisuke Minakata, MD1*, Kaoru Morita, MD, PhD1*, Chihiro Yamamoto, MD, PhD1*, Masahiro Ashizawa, MD1*, Kaoru Hatano, MD, PhD1*, Iekuni Oh, MD, PhD1*, Ken Ohmine, MD, PhD1*, Shin-ichiro Fujiwara, MD, PhD1,2* and Yoshinobu Kanda, MD, PhD1

1Division of Hematology, Jichi Medical University, Shimotsuke, Japan
2Division of Cell Transplantation and Transfusion, Jichi Medical University Hospital, Shimotsuke, Japan

Suguru Tamura, MD1*, Takashi Ushiki, MD, Ph.D2*, Tatsuya Suwabe1*, Takayuki Katagiri, MD1*, Tomoyuki Tanaka, MD1*, Kyoko Fuse, MD, Ph.D1*, Yasuhiko Shibasaki, MD, Ph.D1*, Miwako Narita, MD, Ph.D3, Michihiro Igarashi, MD, PhD4*, Hirohito Sone, MD, Ph.D1* and Masayoshi Masuko, MD, Ph.D1,5

1Department of Hematology, Niigata University Faculty of Medicine, Niigata, Japan
2Department of Transfusion Medicine, Cell Therapy and Regenerative Medicine, Niigata University Faculty of Medicine, Niigata, Japan
3Laboratory of Hematology and Oncology, School of Health Sciences Niigata University, Niigata City, Japan
4Department of Neurochemistry and Molecular Cell Biology,, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
5Division of Transplantation Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan

Jeremy Freeman, PhD1*, Jason Cummings, PhD2*, Marither Chuidian, MD3 and Thomas Dudler, PhD2*

1Nonclinical Department, Omeros Corporation, Seattle, WA
2Discovery, Omeros Corporation, Seattle, WA
3Medical Affairs, Omeros Corporation, Seattle, WA

*signifies non-member of ASH